CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: NUP98 (ImmuneEditome ID:4928)

1. Gene summary of enriched editing regions for NUP98

check button Gene summary
Gene informationGene symbol

NUP98

Gene ID

4928

GeneSynonymsADIR2|NUP196|NUP96|Nup98-96
GeneCytomap

11p15.4

GeneTypeprotein-coding
GeneDescriptionnuclear pore complex protein Nup98-Nup96|nuclear pore complex protein Nup98|GLFG-repeat containing nucleoporin|NUP98/PHF23 fusion 2 protein|Nup98-Nup96|nucleoporin 96|nucleoporin 98kD|nucleoporin 98kDa
GeneModificationdate20230329
UniprotIDP52948;E9PNN0;A0A3B3ITD8
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr11:3689402-3690514:-ENST00000324932.10ENSG00000110713.14NUP98intronicAluJb,AluY,AluSx1chr11:3689402-3690514:-.alignment
chr11:3689402-3690514:-ENST00000355260.6ENSG00000110713.14NUP98intronicAluJb,AluY,AluSx1chr11:3689402-3690514:-.alignment
chr11:3689402-3690514:-ENST00000359171.7ENSG00000110713.14NUP98intronicAluJb,AluY,AluSx1chr11:3689402-3690514:-.alignment
chr11:3689402-3690514:-ENST00000429801.4ENSG00000110713.14NUP98intronicAluJb,AluY,AluSx1chr11:3689402-3690514:-.alignment
chr11:3689402-3690514:-ENST00000524563.1ENSG00000110713.14NUP98intronicAluJb,AluY,AluSx1chr11:3689402-3690514:-.alignment
chr11:3698351-3698964:-ENST00000324932.10ENSG00000110713.14NUP98intronicAluYk11,AluSq2chr11:3698351-3698964:-.alignment
chr11:3698351-3698964:-ENST00000355260.6ENSG00000110713.14NUP98intronicAluYk11,AluSq2chr11:3698351-3698964:-.alignment
chr11:3698351-3698964:-ENST00000359171.7ENSG00000110713.14NUP98intronicAluYk11,AluSq2chr11:3698351-3698964:-.alignment
chr11:3698351-3698964:-ENST00000429801.4ENSG00000110713.14NUP98intronicAluYk11,AluSq2chr11:3698351-3698964:-.alignment
chr11:3698351-3698964:-ENST00000529063.1ENSG00000110713.14NUP98intronicAluYk11,AluSq2chr11:3698351-3698964:-.alignment
chr11:3701279-3702235:-ENST00000324932.10ENSG00000110713.14NUP98intronicAluY,AluSzchr11:3701279-3702235:-.alignment
chr11:3701279-3702235:-ENST00000355260.6ENSG00000110713.14NUP98intronicAluY,AluSzchr11:3701279-3702235:-.alignment
chr11:3701279-3702235:-ENST00000359171.7ENSG00000110713.14NUP98intronicAluY,AluSzchr11:3701279-3702235:-.alignment
chr11:3701279-3702235:-ENST00000429801.4ENSG00000110713.14NUP98intronicAluY,AluSzchr11:3701279-3702235:-.alignment
chr11:3701279-3702235:-ENST00000529063.1ENSG00000110713.14NUP98intronicAluY,AluSzchr11:3701279-3702235:-.alignment
chr11:3721567-3722390:-ENST00000324932.10ENSG00000110713.14NUP98intronicAluJr,A-rich,AluSq,(AATAA)nchr11:3721567-3722390:-.alignment
chr11:3721567-3722390:-ENST00000355260.6ENSG00000110713.14NUP98intronicAluJr,A-rich,AluSq,(AATAA)nchr11:3721567-3722390:-.alignment
chr11:3721567-3722390:-ENST00000359171.7ENSG00000110713.14NUP98intronicAluJr,A-rich,AluSq,(AATAA)nchr11:3721567-3722390:-.alignment
chr11:3721567-3722390:-ENST00000397004.7ENSG00000110713.14NUP98intronicAluJr,A-rich,AluSq,(AATAA)nchr11:3721567-3722390:-.alignment
chr11:3721567-3722390:-ENST00000397007.7ENSG00000110713.14NUP98intronicAluJr,A-rich,AluSq,(AATAA)nchr11:3721567-3722390:-.alignment
chr11:3743048-3743245:-ENST00000324932.10ENSG00000110713.14NUP98intronicAluSgchr11:3743048-3743245:-.alignment
chr11:3743048-3743245:-ENST00000355260.6ENSG00000110713.14NUP98intronicAluSgchr11:3743048-3743245:-.alignment
chr11:3743048-3743245:-ENST00000359171.7ENSG00000110713.14NUP98intronicAluSgchr11:3743048-3743245:-.alignment
chr11:3743048-3743245:-ENST00000397004.7ENSG00000110713.14NUP98intronicAluSgchr11:3743048-3743245:-.alignment
chr11:3743048-3743245:-ENST00000397007.7ENSG00000110713.14NUP98intronicAluSgchr11:3743048-3743245:-.alignment
chr11:3743048-3743245:-ENST00000397013.2ENSG00000110713.14NUP98intronicAluSgchr11:3743048-3743245:-.alignment
chr11:3743048-3743245:-ENST00000527104.4ENSG00000110713.14NUP98intronicAluSgchr11:3743048-3743245:-.alignment
chr11:3743048-3743245:-ENST00000529379.1ENSG00000110713.14NUP98intronicAluSgchr11:3743048-3743245:-.alignment
chr11:3756485-3757604:-ENST00000324932.10ENSG00000110713.14NUP98intronicAluSq2,(AT)n,AluSx,AluYchr11:3756485-3757604:-.alignment
chr11:3756485-3757604:-ENST00000355260.6ENSG00000110713.14NUP98intronicAluSq2,(AT)n,AluSx,AluYchr11:3756485-3757604:-.alignment
chr11:3756485-3757604:-ENST00000359171.7ENSG00000110713.14NUP98intronicAluSq2,(AT)n,AluSx,AluYchr11:3756485-3757604:-.alignment
chr11:3756485-3757604:-ENST00000397004.7ENSG00000110713.14NUP98intronicAluSq2,(AT)n,AluSx,AluYchr11:3756485-3757604:-.alignment
chr11:3756485-3757604:-ENST00000397007.7ENSG00000110713.14NUP98intronicAluSq2,(AT)n,AluSx,AluYchr11:3756485-3757604:-.alignment
chr11:3756485-3757604:-ENST00000397013.2ENSG00000110713.14NUP98intronicAluSq2,(AT)n,AluSx,AluYchr11:3756485-3757604:-.alignment
chr11:3756485-3757604:-ENST00000527104.4ENSG00000110713.14NUP98intronicAluSq2,(AT)n,AluSx,AluYchr11:3756485-3757604:-.alignment
chr11:3756485-3757604:-ENST00000529379.1ENSG00000110713.14NUP98intronicAluSq2,(AT)n,AluSx,AluYchr11:3756485-3757604:-.alignment
chr11:3789569-3790002:-ENST00000324932.10ENSG00000110713.14NUP98intronicAluJr,AluScchr11:3789569-3790002:-.alignment
chr11:3789569-3790002:-ENST00000355260.6ENSG00000110713.14NUP98intronicAluJr,AluScchr11:3789569-3790002:-.alignment
chr11:3789569-3790002:-ENST00000359171.7ENSG00000110713.14NUP98intronicAluJr,AluScchr11:3789569-3790002:-.alignment
chr11:3789569-3790002:-ENST00000397004.7ENSG00000110713.14NUP98intronicAluJr,AluScchr11:3789569-3790002:-.alignment
chr11:3789569-3790002:-ENST00000397007.7ENSG00000110713.14NUP98intronicAluJr,AluScchr11:3789569-3790002:-.alignment
chr11:3789569-3790002:-ENST00000532475.1ENSG00000110713.14NUP98intronicAluJr,AluScchr11:3789569-3790002:-.alignment


Top

2. Tumor-specific enriched editing regions for NUP98


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr11:3698351-3698964:-STADPathEER3.6889e-029.2427e-030.2112image
ENSG00000110713.14,NUP98STADPathEAG3.9007e-031.1176e-020.1642image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000110713.14,NUP98STADEAG1.8717e-022.2837e-028.6306e+00image

Top

3. Enriched editing regions and immune related genes for NUP98


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for NUP98


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000110713.14,NUP98
ESCAEAGESENSG00000145029.7chr349425366:49425438:49425882:49425996:49426251:494264070.31611.6829e-021.3458e-050.4019imageNADAR;AIFM1;AUH;BCCIP;BUD13;CBX7;CELF2;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAEosinophilsGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for NUP98


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr11:3698351-3698964:-BLCAEERMacrophages_M18.8734e-030.3561image
ENSG00000110713.14,NUP98BLCAEAGMacrophages_M19.0978e-030.3518image
chr11:3698351-3698964:-BRCAEERMacrophages_M22.8930e-020.1181image
ENSG00000110713.14,NUP98BRCAEAGT_cells_CD4_memory_resting4.3797e-02-0.1072image
chr11:3698351-3698964:-CESCEERNeutrophils1.3265e-020.3983image
ENSG00000110713.14,NUP98CESCEAGNeutrophils1.2192e-020.3976image
chr11:3698351-3698964:-COADEEREosinophils3.9001e-020.3556image
ENSG00000110713.14,NUP98COADEAGT_cells_regulatory_(Tregs)9.8854e-030.3984image
chr11:3698351-3698964:-ESCAEERPlasma_cells2.3712e-030.3292image
chr11:3701279-3702235:-ESCAEERT_cells_CD4_memory_resting3.6022e-02-0.2860image
chr11:3721567-3722390:-ESCAEERT_cells_CD4_memory_resting3.8794e-03-0.2822image
ENSG00000110713.14,NUP98ESCAEAGPlasma_cells7.7816e-030.2316image
chr11:3698351-3698964:-HNSCEERMonocytes3.6878e-02-0.2448image
ENSG00000110713.14,NUP98HNSCEAGMonocytes3.6878e-02-0.2448image
chr11:3698351-3698964:-LAMLEERNK_cells_activated7.6577e-030.3497image
ENSG00000110713.14,NUP98LAMLEAGMonocytes3.2801e-030.2443image
chr11:3698351-3698964:-OVEERT_cells_CD86.3164e-030.2566image
ENSG00000110713.14,NUP98OVEAGT_cells_CD81.8947e-020.2114image
chr11:3698351-3698964:-PRADEERMast_cells_resting3.7194e-020.2141image
ENSG00000110713.14,NUP98PRADEAGMast_cells_resting4.7760e-030.2479image
chr11:3698351-3698964:-SARCEERMacrophages_M11.0488e-02-0.5585image
ENSG00000110713.14,NUP98SARCEAGMacrophages_M11.0488e-02-0.5585image
chr11:3689402-3690514:-STADEERMacrophages_M02.8316e-020.2786image
chr11:3698351-3698964:-STADEERNeutrophils1.4713e-020.1969image
chr11:3721567-3722390:-STADEERMacrophages_M12.2779e-030.2515image
ENSG00000110713.14,NUP98STADEAGMacrophages_M16.3743e-030.1742image
chr11:3698351-3698964:-THCAEERT_cells_regulatory_(Tregs)2.1212e-030.2642image
ENSG00000110713.14,NUP98THCAEAGT_cells_regulatory_(Tregs)8.7129e-030.2241image
chr11:3698351-3698964:-THYMEEREosinophils4.6056e-030.5806image
ENSG00000110713.14,NUP98THYMEAGEosinophils4.6056e-030.5806image


Top

6. Enriched editing regions and immune gene sets for NUP98


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000110713.14,NUP98BLCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.4541e-040.4793image
chr11:3698351-3698964:-BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.1077e-030.4131image
chr11:3698351-3698964:-BRCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.3579e-02-0.1334image
ENSG00000110713.14,NUP98BRCAGSVA_HALLMARK_DNA_REPAIREAG3.2360e-030.1561image
chr11:3698351-3698964:-COADGSVA_HALLMARK_PEROXISOMEEER3.1261e-04-0.5812image
ENSG00000110713.14,NUP98COADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.6310e-020.3730image
chr11:3698351-3698964:-ESCAGSVA_HALLMARK_KRAS_SIGNALING_DNEER4.3697e-020.2220image
ENSG00000110713.14,NUP98ESCAGSVA_HALLMARK_MYOGENESISEAG1.7691e-040.3220image
chr11:3721567-3722390:-ESCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.0051e-020.2526image
chr11:3701279-3702235:-ESCAGSVA_HALLMARK_MYOGENESISEER8.1714e-030.3564image
chr11:3698351-3698964:-GBMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER2.8378e-030.3618image
ENSG00000110713.14,NUP98GBMGSVA_HALLMARK_MYOGENESISEAG2.4143e-030.3647image
ENSG00000110713.14,NUP98HNSCGSVA_HALLMARK_MYC_TARGETS_V2EAG8.7117e-03-0.3049image
chr11:3698351-3698964:-HNSCGSVA_HALLMARK_MYC_TARGETS_V2EER8.7117e-03-0.3049image
chr11:3698351-3698964:-KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.2986e-020.3360image
ENSG00000110713.14,NUP98KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG7.8489e-030.3487image
chr11:3698351-3698964:-LAMLGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.7929e-020.3126image
ENSG00000110713.14,NUP98LAMLGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG6.5895e-030.2262image
ENSG00000110713.14,NUP98LGGGSVA_HALLMARK_KRAS_SIGNALING_UPEAG2.5778e-030.1902image
chr11:3698351-3698964:-LGGGSVA_HALLMARK_KRAS_SIGNALING_UPEER2.5778e-030.1902image
chr11:3698351-3698964:-LUADGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.7413e-02-0.2589image
ENSG00000110713.14,NUP98OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.3689e-020.2218image
chr11:3698351-3698964:-OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.6408e-020.2098image
ENSG00000110713.14,NUP98PRADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG8.3225e-04-0.2918image
chr11:3698351-3698964:-PRADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.1538e-030.3111image
chr11:3698351-3698964:-SARCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER3.9718e-02-0.4632image
ENSG00000110713.14,NUP98SARCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG3.9718e-02-0.4632image
ENSG00000110713.14,NUP98STADGSVA_HALLMARK_APICAL_SURFACEEAG1.7765e-030.1991image
chr11:3689402-3690514:-STADGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.3808e-030.3974image
chr11:3721567-3722390:-STADGSVA_HALLMARK_FATTY_ACID_METABOLISMEER4.9127e-030.2324image
chr11:3698351-3698964:-STADGSVA_HALLMARK_COMPLEMENTEER2.1469e-050.3362image
chr11:3701279-3702235:-STADGSVA_HALLMARK_FATTY_ACID_METABOLISMEER2.3182e-020.2144image
chr11:3698351-3698964:-TGCTGSVA_HALLMARK_DNA_REPAIREER4.9535e-020.2505image
ENSG00000110713.14,NUP98TGCTGSVA_HALLMARK_DNA_REPAIREAG4.9535e-020.2505image
ENSG00000110713.14,NUP98THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG7.3621e-030.2289image
chr11:3698351-3698964:-THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.1611e-020.2182image
ENSG00000110713.14,NUP98THYMGSVA_HALLMARK_P53_PATHWAYEAG1.0462e-020.5341image
chr11:3698351-3698964:-THYMGSVA_HALLMARK_P53_PATHWAYEER1.0462e-020.5341image
chr11:3698351-3698964:-UCECGSVA_HALLMARK_COAGULATIONEER2.0468e-020.4018image
ENSG00000110713.14,NUP98UCECGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG1.3464e-020.3925image


Top

7. Enriched editing regions and drugs for NUP98


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr11:3698351-3698964:-BLCACI.1040EER2.5224e-03-0.4065image
ENSG00000110713.14,NUP98BLCACCT007093EAG2.4096e-030.4046image
ENSG00000110713.14,NUP98BRCADMOGEAG3.7955e-030.1537image
chr11:3698351-3698964:-BRCABMS.536924EER1.1415e-020.1370image
chr11:3698351-3698964:-CESCDMOGEER2.9878e-02-0.3527image
ENSG00000110713.14,NUP98COADCGP.60474EAG7.8455e-03-0.4095image
chr11:3698351-3698964:-COADCCT007093EER4.9630e-04-0.5652image
chr11:3721567-3722390:-ESCAGNF.2EER4.7151e-05-0.3897image
chr11:3698351-3698964:-ESCADMOGEER4.1194e-03-0.3117image
chr11:3701279-3702235:-ESCABexaroteneEER5.7443e-03-0.3710image
ENSG00000110713.14,NUP98ESCAAZD.0530EAG3.6403e-05-0.3525image
chr11:3698351-3698964:-GBMImatinibEER5.9155e-03-0.3353image
ENSG00000110713.14,NUP98GBMImatinibEAG4.2277e-03-0.3452image
ENSG00000110713.14,NUP98HNSCDMOGEAG6.9818e-03-0.3132image
chr11:3698351-3698964:-HNSCDMOGEER6.9818e-03-0.3132image
ENSG00000110713.14,NUP98LAMLGefitinibEAG2.0416e-020.1938image
chr11:3698351-3698964:-LGGDocetaxelEER1.5384e-040.2376image
ENSG00000110713.14,NUP98LGGDocetaxelEAG1.5384e-040.2376image
ENSG00000110713.14,NUP98LUSCFH535EAG4.8127e-02-0.2002image
ENSG00000110713.14,NUP98OVCytarabineEAG1.0004e-020.2314image
chr11:3698351-3698964:-OVFH535EER6.4488e-030.2560image
ENSG00000110713.14,NUP98PRADGemcitabineEAG3.7752e-070.4311image
chr11:3698351-3698964:-PRADBleomycinEER2.5429e-020.2293image
chr11:3698351-3698964:-SARCABT.263EER4.4126e-030.6085image
ENSG00000110713.14,NUP98SARCABT.263EAG4.4126e-030.6085image
chr11:3698351-3698964:-SKCMElesclomolEER1.3010e-030.3795image
ENSG00000110713.14,NUP98STADKU.55933EAG1.9827e-02-0.1491image
chr11:3689402-3690514:-STADLapatinibEER5.2722e-05-0.4937image
chr11:3721567-3722390:-STADBAY.61.3606EER1.2519e-020.2069image
chr11:3698351-3698964:-STADAZ628EER4.9092e-03-0.2263image
chr11:3701279-3702235:-STADAG.014699EER1.5273e-02-0.2287image
ENSG00000110713.14,NUP98TGCTCamptothecinEAG2.0596e-02-0.2935image
chr11:3698351-3698964:-TGCTCamptothecinEER2.0596e-02-0.2935image
ENSG00000110713.14,NUP98THCAKU.55933EAG3.9996e-04-0.2993image
chr11:3698351-3698964:-THCAKU.55933EER3.9920e-04-0.3026image
ENSG00000110713.14,NUP98THYMAZD6244EAG1.4398e-03-0.6368image
chr11:3698351-3698964:-THYMAZD6244EER1.4398e-03-0.6368image
ENSG00000110713.14,NUP98UCECAZD7762EAG2.8496e-02-0.3509image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType